- What is Matricelf's primary focus in regenerative medicine?
- Matricelf is a regenerative medicine company developing personalized, autologous engineered neural tissue for the treatment of spinal cord injury. Their technology combines patient-derived cells and biomaterials to create patient-specific implants.
- When did Matricelf go public and on which exchange?
- Matricelf went public in June 2021 with an IPO on the TASE (Tel Aviv Stock Exchange), raising $7.4 million at a valuation of $22 million.
- What was a significant product development milestone for Matricelf in June 2026?
- In June 2026, Matricelf began manufacturing experimental implants for a spinal cord injury trial, advancing towards their first-in-human trial with the initiation of a GMP manufacturing program.
- What strategic collaboration did Matricelf enter into in March 2026?
- In March 2026, Matricelf entered a strategic collaboration with Japan's CiRA Foundation to advance next-generation regenerative manufacturing.
- What is Matricelf's current employee count?
- Matricelf has 11-50 employees.
- What was a key leadership appointment for Matricelf in February 2026?
- In February 2026, Matricelf appointed Ron Mayron as Chairman of the Board.
- What was the outcome of Matricelf's RNA sequencing results reported in March 2026?
- In March 2026, Matricelf reported positive RNA sequencing results, demonstrating a promising safety profile for its personalized spinal cord implant.
- What is Matricelf's lead program targeting?
- Matricelf's lead program targets spinal cord injury (SCI), with preclinical studies showing compelling safety and functional recovery.
